SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.
| Revenue (Most Recent Fiscal Year) | $20.60M |
| Net Income (Most Recent Fiscal Year) | $-8.61M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.38 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -120.51% |
| Net Margin (Trailing 12 Months) | -41.79% |
| Return on Equity (Trailing 12 Months) | -57.16% |
| Return on Assets (Trailing 12 Months) | -39.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 5.58M |
| Free Float | 5.36M |
| Market Capitalization | $28.47M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |